# Atomoxetine to Treat Asian Adult Patients With Attention-Deficit/Hyperactivity Disorder

> **NCT00962104** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 391 (actual)

## Conditions studied

- Attention Deficit Hyperactivity Disorder

## Interventions

- **DRUG:** Atomoxetine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00962104
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08
- **Primary completion:** 2011-02
- **Final completion:** 2011-02
- **Target enrollment:** 391 (ACTUAL)
- **Last updated:** 2012-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00962104

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00962104, "Atomoxetine to Treat Asian Adult Patients With Attention-Deficit/Hyperactivity Disorder". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00962104. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*